VC-backed Aquinox Pharmaceuticals prices IPO to raise over $46 mln
Aquinox Pharmaceuticals Inc has priced its initial public offering (IPO) of 4.2 million common shares at $11.00 per share. The IPO is intended to raise gross proceeds of $46.2 million. Aquinox's stock has been approved for a NASDAQ listing and is expected to begin trading immediately under the symbol AQXP. Based in Vancouver, Aquinox is a clinical-stage biotech company that develops novel and targeted small molecule therapeutics for the treatment of inflammatory disease. It has been backed by Canadian and U.S. venture capital firms since 2007. In April 2013, the company secured a US$18 million Series C financing led by Johnson & Johnson Development Corp.
7 March 2014•2 mins read
